27 October 2020: Review Paper
Prognosis and Treatment of Liver Transplant Recipients in the COVID-19 Era: A Literature Review
Ashraf Imam 1ADEFG* , Sadi A. Abukhalaf 1ABCDEF* , Hadar Merhav 1CDFG , Samir Abu-Gazala 1ABDG , Oded Cohen-Arazi 1BCEG , Alon Josef Pikarsky 1DEFG , Rifaat Safadi 2EFG** , Abed Khalaileh 1AEFG***DOI: 10.12659/AOT.926196
Ann Transplant 2020; 25:e926196
Table 2 Clinical characteristics of the 22 reported liver transplant patients infected with COVID-19 compared with previous published studies.
| Variable | This study | Webb et al. [11] | Pooled (mean) |
|---|---|---|---|
| Number of patients | 22 | 39 | 61 |
| Age (Mean) | 55.96 | 60.50 | 58.25 |
| Sex | |||
| Male | 68.2% | 64.1% | 66.15% |
| Liver transplant years age (mean) | 8.75 | 5.5 | 7.125 |
| Comorbidities | |||
| HTN | 18.2% | 46.2% | 32.2% |
| DM | 22.7% | 38.5% | 30.6% |
| Heart disease | 22.7% | 15.4% | 19% |
| Obesity | 4.6% | 25.7% | 15.15% |
| Baseline Immunosuppression | |||
| Tacrolimus | 68.2% | 89.7% | 79% |
| Mycophenolate mofetil | 45.5% | 51.3% | 48.4% |
| Prednisone | 18.2% | 41% | 29.6% |